Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + PF-04518600
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Avelumab + PF-04518600 is a combination of two monoclonal antibodies developed for cancer immunotherapy. Avelumab is a fully human IgG1 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as a checkpoint inhibitor to potentiate anti-tumor immune responses. PF-04518600 (also known as ivuxolimab) is a humanized IgG2 agonist monoclonal antibody that targets OX40 (also known as CD134), a co-stimulatory receptor on activated T cells, promoting T cell proliferation, survival, and effector function. This combination is under clinical investigation for use in various advanced or metastatic solid tumors, with the aim of harnessing both checkpoint blockade and co-stimulatory immune activation for greater anti-tumor efficacy[1][2][4][6][7]. Trials are conducted primarily with intravenous administration.
- Brand names
- Bavencio
- Other names
- MSB0010718C (avelumab)ivuxolimab (PF-04518600)
02
Targets
CD28 (Cluster of Differentiation 28)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on avelumab + PF-04518600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + PF-04518600.